BioStem Technologies Reports Q3 2026 Results with Revenue Decline and Increased EBITDA Loss
BioStem Technologies (BSEM) reported third-quarter 2026 net revenue of $7.6 million, a sequential decrease from $7.9 million in the previous quarter. The decline was primarily driven by lower contributions from the physician office channel as the company strategically shifts resources toward its hospital segment, which saw a 2% sequential growth to $6.8 million. The company's financial position faced pressure with an adjusted EBITDA loss of $6.4 million, up from $4.6 million in Q2. Gross margins fell to 56% due to the expiration of initial discounts under the BioTissue supply agreement. Despite these headwinds, management raised full-year 2026 revenue guidance to a range of $28 million to $29 million, citing strong performance in the hospital channel and expansion through group purchasing organizations.
Tickers: $BSEM
Topics: EBITDA loss gross margin compression operating expenses revenue decline